ADMA Biologics Reports Strong Q3 2026 Growth Driven by ASCENIV and Margin Expansion
ADMA Biologics (ADMA) reported robust third-quarter 2026 financial results, highlighted by a 5% year-over-year increase in total revenue to $141.1 million. The company's growth was primarily driven by its ASCENIV product line, which saw a 31% year-over-year revenue surge due to increased physician adoption and new patient starts. This momentum contributed to significant profitability improvements, with Adjusted EBITDA growing 32% year-over-year to $77.3 million. Despite competitive pricing pressures affecting BIVIGAM revenues, ADMA achieved a substantial gross margin expansion of 1,450 basis points due to favorable product mix and manufacturing efficiencies. Looking ahead, the company raised its full-year guidance for Adjusted EBITDA and Net Income, citing continued commercial momentum. Management also highlighted progress with their SG-001 candidate, noting constructive FDA feedback for future Phase III studies.
Tickers: $ADMA
Topics: Adjusted EBITDA Cash Flow Gross Margin Expansion Revenue Growth Share Repurchases